What is known and objective: It is 20 years since the US Food and Drug Administration approved the first successful monoclonal anticancer antibody, trastuzumab. The therapeutic utility of monoclonal antibodies in cancer is often limited by partial clinical responses and the development of tumour resistance. An expanding strategy, to be reviewed here, to overcome the limited response and resistance to monotherapy utilizes concurrent treatment with two synergistic monoclonal antibodies.
| WHAT IS K NOWN AND OBJEC TIVE
Much has changed over the last 20 years. mAbs have now been adapted to treat a wide array of illnesses, including other cancers, autoimmune diseases, hyperlipidaemia and blood disorders, 3 and their mechanisms of action are equally diverse. Theoretically, their potential clinical application is limited only by our understanding of disease aetiology. 3, 6 Consequently, in recent years, mAbs and related products have been the fastest growing class of therapeutic agents.
However, the mAbs are expensive therapeutic options. It has been reported that the global market for mAbs topped $100 billion in 2017. 7 In Australia, three mAbs (adalimumab, ranibizumab and denosumab) were in the top 10 drugs for highest government cost under the Pharmaceutical Benefits Scheme for 2016-2017, with a combined cost exceeding Aus$650M. 8 Twenty years ago, we were wondering how the health system would afford these agents. 9 Now, the decision-makers have a new economic concern-how to pay for the increasingly common approach of using two mAbs in combination. Combining anticancer therapies has been essential to achieve complete remission and cures for patients. This has now extended to combining mAbs. 10 Here, we provide an overview of the rationale and evidence for using selected mAbs in combination for treating some cancers.
| COMMENT
The therapeutic utility and widespread use of mAbs in cancer is often limited by partial and transient clinical responses, as well as the development of tumour resistance. An expanding strategy to overcome resistance utilizes concurrent treatment with two or more mAbs. 4 Key examples to date include the first homo-combination of two mAbs, each engaging a distinct site of HER2, in the treatment of breast cancer and a hetero-combination of antibodies to two distinct T-cell antigens, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the programmed cell death-1 (PD-1) T-cell receptor, for the treatment of melanoma.
| Breast cancer
The first time that FDA approved a molecularly targeted mAb to be used in combination with another mAb was on June 8, 2012, when the combination of pertuzumab and trastuzumab, with docetaxel, was approved for the treatment of patients with HER2-positive metastatic breast cancer. Trastuzumab directly binds to the extracellular domain IV of HER2 and cause its degradation.
Pertuzumab binds to a different epitope on HER2 than trastuzumab, blocking the formation of HER2:HER3 heterodimers, which is believed to be an important mechanism of resistance to trastuzumab. As a single agent, pertuzumab displays only modest antitumour activity.
Approval for the combination pertuzumab-trastuzumab therapy was based on the results of a randomized, double-blind, placebocontrolled trial conducted in 808 patients with HER2-positive metastatic breast cancer. 11, 12 Patients received pertuzumab (n = 402) or placebo (n = 406) in combination with trastuzumab and docetaxel.
The primary endpoint was progression-free survival (PFS) and a key secondary endpoint was overall survival (OS The Phase III Checkmate 067 study enrolled 945 patients with advanced melanoma into three arms: ipilimumab, nivolumab and the combination of these two agents. 27, 28 The trial was designed and powered to compare single-agent nivolumab and the combination regimen against single-agent ipilimumab, the standard treatment at the time. The study was not designed or powered to compare the nivolumab and the combination. The median PFS was superior for ipilimumab plus nivolumab (11.5 months; 95% CI, 8.9-16.7) compared with the nivolumab arm (6.9 months; 95% CI, 4.3-9.5) and the ipilimumab arm (2.9 months; 95% CI, 2.8-3.4; P < 0.001). 27 The OS data demonstrated that both experimental arms were associated with significant improvements compared with ipilimumab monotherapy. The OS rate at 3 years was 58% in the nivolumab-plus-ipilimumab group and 52% in the nivolumab group (difference not statistically significant), as compared with 34% in the ipilimumab group. 28 Patients with 1% or greater tumour expression of PD-L1 did as well with nivolumab alone as with the combination therapy, while only patients with no tumour expression of PD-L1 benefited from the combination.
In a review of the results, Turajlic et al 29 There is considerable interest in the use of combined anti-CTLA-4 and anti-PD-1/anti-PD-L1 therapy in non-small-cell lung cancer (NSCLC), where pembrolizumab is already first-line therapy in patients with tumours displaying strong PD-L1 expression. 23, 30, 32 In a Phase I study (CheckMate 012) of 78 patients with advanced NSCLC, the combination of nivolumab-plus-ipilimumab showed encouraging results by means of a relatively high response and tolerable safety profile. 33 Clinical activity was particularly enhanced in patients whose tumours expressed PD-L1 on at least 1% of their cancer cells (objective responses were achieved in 57%).
However, it was recently reported that durvalumab, either alone or in combination with tremelimumab, did not improve PFS in previously untreated patients with stage IV metastatic NSCLC compared with standard platinum-based chemotherapy (MYSTIC trial). 34 The
Phase III trial will continue to assess two additional primary endpoints of OS for durvalumab monotherapy and the durvalumab/ tremelimumab combination. A similar negative outcome was reported in a separate trial of patients with locally advanced or metastatic NSCLC who had received at least two prior treatments (ARCTIC trial). 35 In contrast, the combination of durvalumab and tremelimumab has shown promising activity in mesothelioma in a Phase II study. 36 The addition of atezolizumab to bevacizumab (mAb inhibitor of vascular endothelial growth factor; VEGF) plus chemotherapy (carboplatin and paclitaxel) significantly improved PFS and OS among previously untreated patients with metastatic nonsquamous NSCLC. 37 The addition of atezolizumab increased the median PFS from 6.8 to 8.3 months (HR for disease progression or death, 0.62; 95% CI, 0.52-0.74; P < 0.001).
| Adverse reactions
A major clinical concern with the use of combined checkpoint inhibitor therapy is the risk of adverse reactions, particularly as a result of overstimulating the immune system. Incremental toxicity that can result from immunotherapeutic combinations is dependent on both the patient population and the dose and schedule that is utilized, emphasizing the importance of carefully planned Phase I dose-finding trials. 10, 20 Immune-related adverse reactions can potentially affect any tissue but mainly involve the gut (diarrhoea and/or colitis), skin (eg maculopapular rash and pruritus), endocrine glands (eg hypopituitarism and thyroid abnormalities), liver (typically asymptomatic hepatitis characterized by elevated alanine aminotransferase or aspartate aminotransferase, with or without raised bilirubin) and lung (eg pneumonitis and pleural effusions), while cardiovascular, haematologic, renal, neurologic and ophthalmologic immune-related adverse events occur much less frequently. 38, 39 The majority of immune-related adverse reactions are mild to moderate in severity; however, serious and occasionally life-threatening adverse reactions are reported in the literature, and treatment-related deaths occur in up to 2% of patients. 39 These immune-related adverse reactions events are generally manageable with the administration of high-dose glucocorticoids, although the associated immunosuppression may compromise the antitumour response.
38,40
The combination of ipilimumab and nivolumab in patients with advanced melanoma is associated with significant toxicity, with around one-third of patients discontinuing treatment as a result. In the Phase III Checkmate 067 study, treatment-related adverse events of grade 3 or 4 occurred in 59% of the patients in the nivolumab-plus-ipilimumab group, in 21% of those in the nivolumab group, and in 28% of those in the ipilimumab group. In the recent study of patients with advanced renal-cell carcinoma, nivolumab-plus-ipilimumab was associated with a lower incidence of grade 3 and 4 treatment-related adverse events than observed with sunitinib. 31 The frequencies of treatment-related gastrointestinal, skin, and hepatic adverse events were lower than those seen in trials of patients with melanoma, typically involving a higher dose of ipilimumab. or with not-yet-discovered better immunotherapies. 18, 20, 21, 23, [42] [43] [44] Individualization will extend to combination regimen dosing schedules and durations of therapy. There is likely to be an infinite grid of therapeutic possibilities, each of which needs to be considered carefully. 45 Importantly, the increased potential for immunological adverse events must be anticipated. 4, 10, 20, 45 How to meet the substantial costs of these therapies will, unfortunately, be an ongoing concern.
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